If children ruled the pharmaceutical industry: The need for pediatric formulations

Drug News and Perspectives

Volumn 23, Issue 7, 2010, Pages 458-464

  Rieder, Michael ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b The Children's Health Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CEFALEXIN; CLOXACILLIN; CODEINE; DIPHENHYDRAMINE; ERYTHROMYCIN; FUSIDIC ACID; PRESCRIPTION DRUG; SALBUTAMOL; SULFANILAMIDE; THALIDOMIDE; DRUG;

AFRICAN AMERICAN; AGE; ALLERGY; ANTIMICROBIAL THERAPY; ASTHMA; BACTERIAL MENINGITIS; BENIGN CHILDHOOD EPILEPSY; CANADA; CHILDHOOD; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CULTURAL FACTOR; DEPRESSION; DRUG APPROVAL; DRUG CAPSULE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG FORMULARY; DRUG FORMULATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; DRUG USE; ELIXIR; GENETIC POLYMORPHISM; HUMAN; INFANT MORTALITY; PALATABILITY; PEDIATRICS; PHOCOMELIA; PREGNANCY; PRESCRIPTION; REVIEW; ARTICLE; CHILD; DRUG CONTROL; DRUG DESIGN; HEALTH CARE POLICY; METHODOLOGY; ORGANIZATION AND MANAGEMENT;

CHILD; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; DRUG INDUSTRY; HEALTH POLICY; HUMANS; PEDIATRICS; PHARMACEUTICAL PREPARATIONS;

EID: 79952117871     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.7.1458283     Document Type: Review

References (63)

1. Bideau, A., Desjardins, B., Pérez Brignoli, H., (Eds.). Infant and Child Mortality in the Past. Claredon Press: Oxford 1997.
2. Bonanni, P. Demographic impact of vaccination: a review. Vaccine 1999, 17(Suppl 3): S120-5.
3. Weinshilboum, R.M. The therapeutic revolution. Clin Pharmacol Ther 1987, 42(5): 481-4. (Pubitemid 18002162)
4. Thomas, L. The Youngest Science: Notes of a Medicine-Watcher. Viking Press: New York 1983.
5. Rieder, M.J. Perspectives on interactions between paediatricians and the pharmaceutical industry. Paediatr Child Health 2005, 10(3): 147-8. (Pubitemid 40559130)
6. Rice, L.B. Collateral damage. Ann Intern Med 2003, 139(6): 523-4. (Pubitemid 38124578)
7. Wax, P.M. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med 1995, 122(6): 456-61.
8. McBride, W.G. Thalidomide and congenital malformations. Lancet 1961, 2: 1358.
9. Lenz, W. Kindliche missbildungen nach medikameteinnahme wahrend der graviditat? Dtsch Med Wochensche 1961, 86: 2555-6.
10. Blattner, R.J. Drugs in pregnancy-thalidomide. J Pediatr 1962, 61: 153-5.
11. Burgio, G.R. The thalidomide disaster briefly revisited. Eur J Pediatr 1981, 136(3): 229-30. (Pubitemid 11093111)
12. Kauffman, R.E. Status of drug approval processes and regulation of medications for children. Curr Opin Pediatr 1995, 7(2): 195-8.
13. Shirkey, H.C. Editorial comment: therapeutic orphans. J Pediatr 1968, 72: 119-20.
14. Done, A.K., Cohen, S.N., Strebel, L. Pediatric clinical pharmacology and the "therapeutic orphan". Annu Rev Pharmacol Toxicol 1977, 17: 561-73.
15. Wilson, J.T. An update on the therapeutic orphan. Pediatrics 1999, 104(3 Pt 2): 585-90. (Pubitemid 29426624)
16. Ceci, A., Felisi, M., Baiardi, P. et al. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol 2006, 62(11): 947-52. (Pubitemid 44657629)
17. Bleicher, E.W. Encouraging research and development of pediatric medical devices through legislative and regulatory action: the Pediatric Medical Device Safety and Improvement Act of 2007 in context. Food Drug Law J 2009, 64(3): 531-64.
18. Waisel, D.B. Moral responsibility to attain thorough pediatric drug labeling. Paediatr Anaesth 2009, 19(10): 989-93.
19. Hawcutt, D.B., Smyth, R.L. Drug development for children: how is pharma tackling an unmet need? IDrugs 2008, 11(7): 502-7.
20. Rodriguez, W., Selen, A., Avant, D. et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 2008, 121(3): 530-9.
21. Lasky, T. Estimates of pediatric medication use in the United States: current abilities and limitations. Clin Ther 2009, 31(2): 436-45.
22. Rieder, M.J., Matsui, D., MacLeod, S. Myths and challenges - Drug utilization by Canadian children. Paediatr Child Health 2003, 8(Suppl. A): 7A-8A.
23. Turner, M.A., Lewis, S., Hawcutt, D.B., Field, D. Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr 2009, 9: 50.
24. Neubert, A., Lukas, K., Leis, T., Dormann, H., Brune, K., Rascher, W. Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol, 66(1): 87-95.
25. Vernacchio, L., Kelly, J.P., Kaufman, D.W., Mitchell, A.A. Medication use among children <12 years of age in the United States: results from the Slone Survey. Pediatrics 2009, 124(2): 446-54.
26. Clavenna, A., Bonati, M. Drug prescriptions to outpatient children: a review of the literature. Eur J Clin Pharmacol 2009, 65(8): 749-55.
27. James, L., Ito, S. Neonatal pharmacology: rational therapeutics for the most vulnerable. Clin Pharmacol Ther 2009, 86(6): 573-7.
28. Lindell-Osuagwu, L., Korhonen, M.J., Saano, S., Helin-Tanninen, M., Naaranlahti, T., Kokki, H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 2009, 34(3): 277-87.
29. Nunn, T., Williams, J. Formulation of medicines for children. Br J Clin Pharmacol 2005, 59(6): 674-6. (Pubitemid 40835500)
30. Meltzer, E.O., Welch, M.J., Ostrom, N.K. Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr (Phila) 2006, 45(8): 725-33. (Pubitemid 44359192)
31. The Royal Children's Hospital Melbourne. Teach children how to swallow tablets and capsules. A guide for parents, caregivers and children over 4 years. http://www.rch.org.au/pharmacy/clinical/index.cfm?doc-id=2098. Accessed August 25, 2010.
32. University of Michigan Health System. Helping children swallow medicines. http://www.med.umich.edu/1libr/pa/pa-swallmed-hhg.htm.
33. World Health Organisation. WHO Model Lists of Essential Medicines. http://www.who.int /medicines/publications/essentialmedicines/ en/. Accessed August 25, 2010.
34. Braine, T. WHO to launch first essential medicines list for children. Bull World Health Organ 2007, 85(4): 249-50. (Pubitemid 46556721)
35. Ernest, T.B., Elder, D.P., Martini, L.G., Roberts, M., Ford, J.L. Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol 2007, 59(8): 1043-55. (Pubitemid 47265351)
36. Strickley, R.G., Iwata, Q., Wu, S., Dahl, T.C. Pediatric drugs - a review of commercially available oral formulations. J Pharm Sci 2008, 97(5): 1731-74.
37. Matsui, D. Current issues in pediatric medication adherence. Paediatr Drugs 2007, 9(5): 283-8. (Pubitemid 47557110)
38. Nahata, M.C., Allen, L.V., Jr. Extemporaneous drug formulations. Clin Ther 2008, 30(11): 2112-9.
39. Ayenew, Z., Puri, V., Kumar, L., Bansal, A.K. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat Drug Deliv Formul 2009, 3(1): 26-39.
40. Cram, A., Breitkreutz, J., Desset-Brethes, S., Nunn, T., Tuleu, C. Challenges of developing palatable oral paediatric formulations. Int J Pharm 2009, 365(1-2): 1-3.
41. Mennella, J.A., Beauchamp, G.K. Optimizing oral medications for children. Clin Ther 2008, 30(11): 2120-32.
42. Gardiner, P., Dvorkin, L. Promoting medication adherence in children. Am Fam Physician 2006, 74(5): 793-8.
43. Craig, S.R., Adams, L.V., Spielberg, S.P., Campbell, B. Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes. Soc Sci Med 2009, 69(11): 1681-90.
44. Matsui, D., Barron, A., Rieder, M.J. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacother 1996, 30(6): 586-8. (Pubitemid 26184408)
45. Matsui, D., Lim, R., Tschen, T., Rieder, M.J. Assessment of the palatability of beta-lactamase- resistant antibiotics in children. Arch Pediatr Adolesc Med 1997, 151(6): 599-602. (Pubitemid 27262286)
46. Angelilli, M.L., Toscani, M., Matsui, D.M., Rieder, M.J. Palatability of oral antibiotics among children in an urban primary care center. Arch Pediatr Adolesc Med 2000, 154(3): 267-70. (Pubitemid 30131908)
47. Hames, H., Seabrook, J.A., Matsui, D., Rieder, M.J., Joubert, G.I. A palatability study of a flavored dexamethasone preparation versus prednisolone liquid in children. Can J Clin Pharmacol 2008, 15(1): e95-8.
48. Cohen, R., de La Rocque, F., Lecuyer, A., Wollner, C., Bodin, M.J., Wollner, A. Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. Eur J Pediatr 2009, 168(7): 851-7.
49. Anand, V., Kataria, M., Kukkar, V., Saharan, V., Choudhury, P.K. The latest trends in the taste assessment of pharmaceuticals. Drug Discov Today 2007, 12(5-6): 257-65.
50. Thomson, S.A., Tuleu, C., Wong, I.C., Keady, S., Pitt, K.G., Sutcliffe, A.G. Minitablets: new modality to deliver medicines to preschool-aged children. Pediatrics 2009, 123(2): e235-8.
51. Breitkreutz, J., Boos, J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007, 4(1): 37-45.
52. Breitkreutz, J. European perspectives on pediatric formulations. Clin Ther 2008, 30(11): 2146-54.
53. Goel, H., Rai, P., Rana, V., Tiwary, A.K. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul 2008, 2(3): 258-74.
54. Wong, I.C., Wong, L.Y., Cranswick, N.E. Minimising medication errors in children. Arch Dis Child 2009, 94(2): 161-4.
55. Kozer, E., Scolnik, D., Jarvis, A.D., Koren, G. The effect of detection approaches on the reported incidence of tenfold errors. Drug Saf 2006, 29(2): 169-74. (Pubitemid 43213890)
56. Crouch, B.I., Caravati, E.M., Moltz, E. Tenfold therapeutic dosing errors in young children reported to U.S. poison control centers. Am J Health Syst Pharm 2009, 66(14): 1292-6.
57. Milne, C.P., Bruss, J.B. The economics of pediatric formulation development for off-patent drugs. Clin Ther 2008, 30(11): 2133-45.
58. Gazarian, M. Delivering better medicines to children: need for better integration between the science, the policy, and the practice. Paediatr Drugs 2009, 11(1): 41-4.
59. Gray, A. Pediatric pharmacotherapy issues in Africa. Paediatr Drugs 2009, 11(1): 6-8.
60. Madadi, P., Ross, C.J., Hayden, M.R., Carleton, B.C., Gaedigk, A., Leeder, J.S., Koren, G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009, 85(1): 31-5.
61. Ciszkowski, C., Madadi, P., Phillips, M.S., Lauwers, A.E., Koren, G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 2009, 361(8): 827-8.
62. Pepino, M.Y., Mennella, J.A. Factors contributing to individual differences in sucrose preference. Chem Senses 2005, 30(Suppl 1): i319-20.
63. Brieger, W.R., Salami, K.K., Oshiname, F.O. Perception of drug color among drug sellers and consumers in rural southwestern Nigeria. Soc Admin Pharm 2007, 3: 309-19.